Condition
Locally Advanced Unresectable or Metastatic Solid Tumors
Total Trials
5
Recruiting
4
Active
4
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
P 1 (5)
Trial Status
Recruiting4
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05458219Phase 1RecruitingPrimary
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
NCT06170190Phase 1CompletedPrimary
A Multicentre,Study of IBI133 in Subjects WithUnresectable, Locally Advanced or Metastatic SolidTumours
NCT05857332Phase 1RecruitingPrimary
SG1906 for CLDN18.2-Positive Solid Tumors
NCT05978492Phase 1RecruitingPrimary
A Study of TXN10128 in Subjects With Solid Tumors
NCT05636215Phase 1RecruitingPrimary
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Showing all 5 trials